During the corresponding time, Firefly Neuroscience Inc recorded a revenue increase by 71.91 % year on year, sequentially revenue grew by 5.98 %. While revenue at the Firefly Neuroscience Inc 's corporate clients
Firefly Neuroscience Inc's Comment on Sales, Marketing and Customers
The company provides services to a range of clinical settings, from individual practitioners conducting a limited number of monthly assessments to larger multi-provider clinics and health systems with higher patient volumes. Their Evoke System supports clinical decision-making by adding an objective electrophysiological component to existing assessment tools such as the MoCA, MMSE, PHQ-9, and GAD-7. The platform is utilized in neuropsychiatric evaluations across more than 12 disorder categories, including depression, anxiety, ADHD, PTSD, mild cognitive impairment (MCI), dementia, Parkinson's disease, bipolar disorder, schizophrenia, schizoaffective disorder, autism spectrum disorder (ASD), and traumatic brain injury. A primary application of the system is the early detection of cognitive decline, including MCI and early Alzheimer's disease, by distinguishing electrophysiological signatures of cognitive impairment from those of depression. The system supports clinical judgment by integrating behavioral assessments with direct neural measurements to assist clinicians in diagnostic and treatment planning decisions.
: Firefly Neuroscience, a pioneering company in the field of artificial intelligence, is making significant strides in the realm of neuroscience drug development through the advancement of its Brain Network Analytics (BNA) technology. Following successful collaborations with major pharmaceutical institutions, Takeda and Novartis, Firefly s innovations promise to reshape how we understand and treat neurological and mental disorders. This article outlines the critical developments in Firefly s BNA technology and assesses their potential impact on the company and the broader landscape of neuropharmaceutical research. Background: Firefly Neuroscience has emerged as a key player in leveraging artificial intel...
Firefly Neuroscience Inc’s Comment on Sales, Marketing and Customers
The company provides services to a range of clinical settings, from individual practitioners conducting a limited number of monthly assessments to larger multi-provider clinics and health systems with higher patient volumes. Their Evoke System supports clinical decision-making by adding an objective electrophysiological component to existing assessment tools such as the MoCA, MMSE, PHQ-9, and GAD-7. The platform is utilized in neuropsychiatric evaluations across more than 12 disorder categories, including depression, anxiety, ADHD, PTSD, mild cognitive impairment (MCI), dementia, Parkinson's disease, bipolar disorder, schizophrenia, schizoaffective disorder, autism spectrum disorder (ASD), and traumatic brain injury. A primary application of the system is the early detection of cognitive decline, including MCI and early Alzheimer's disease, by distinguishing electrophysiological signatures of cognitive impairment from those of depression. The system supports clinical judgment by integrating behavioral assessments with direct neural measurements to assist clinicians in diagnostic and treatment planning decisions.
Sources:
Firefly Neuroscience Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Firefly Neuroscience Inc’s corporate clients.
For your research, we’ve provided 9 tables on Firefly Neuroscience Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
3.11 %